Govt caps trade margins on 137 anti-cancer drugs at 30%; revised prices from November 9 - The Tribune
The measure covers a range of expensive cancer medicines, including targeted therapies and immunotherapies such as pembrolizumab, nivolumab, osimertinib, palbociclib, ribociclib, abemaciclib, atezolizumab and bevacizumab